Feature

Liver cancer deaths expected to increase again in 2018


 

Liver cancer mortality for 2018 is expected to be lowest in Utah and highest in Hawaii.

A total of 30,200 deaths from liver and intrahepatic bile duct cancer are predicted for the year in the United States by the American Cancer Society (ACS) in its Cancer Facts & Figures 2018, based on analysis of 2001-2015 data from the National Center for Health Statistics. That’s up from the 28,920 predicted by the ACS for 2017.

Estimated liver cancer death rates for 2018
The expected number of liver cancer deaths for 2018, coupled with a current U.S. population estimate of nearly 326 million, works out to an expected death rate of 9.3 per 100,000 population. Census Bureau estimates for the state populations and the deaths projected by the ACS produce expected death rates of 4.8 per 100,000 for Utah and 12.6 for Hawaii.

Mortality from liver cancer has been rising since the early 1980s, and in the last 10 years for which data are available (2006-2015), it increased by 2.5% per year. Over almost the same period (2005-2014), incidence rose by approximately 3% a year, and 42,220 new cases are expected in 2018, the ACS noted.

Over the most recent 5 years with available data (2011-2015), racial and ethnic disparities put American Indian/Alaska Natives at the highest mortality risk – 14.8 per 100,000 for men and 7.0 for women – followed by Asian/Pacific Islanders at 14.0 and 6.0, respectively. Non-Hispanic whites had the lowest rates: 8.2 for men and 3.4 for women, according to the ACS report.

Read more about the ACS’s research and estimates here.

Recommended Reading

Model validates use of HCV+ livers for transplant
MDedge Internal Medicine
Amyloid depleter/antibody duo reduces systemic amyloidosis severity
MDedge Internal Medicine
Risks identified for drug-resistant bacteremia in cirrhosis
MDedge Internal Medicine
Baby boomers are the hepatitis C generation
MDedge Internal Medicine
FDA adds boxed warning to obeticholic acid label
MDedge Internal Medicine
Psychiatric issues common among hepatitis C inpatients
MDedge Internal Medicine
Obesity affects diagnosis of liver fibrosis with imaging techniques
MDedge Internal Medicine
HCV screening, care inadequate for young adults who use opioids nonmedically
MDedge Internal Medicine
National Early Warning Score discriminates deterioration of inpatients with liver disease
MDedge Internal Medicine
Three in 10 of your diabetic patients may have liver fibrosis
MDedge Internal Medicine

Related Articles